PDF(2470 KB)
Bioinformatics analysis based on expression of splicing factor SRSF9 in head and neck squamous cell carcinoma and clinical significance
Yuting LIU,Ying YU,Guizhen LI,Qinxue SHI,Binbin LI
PDF(2470 KB)
PDF(2470 KB)
Bioinformatics analysis based on expression of splicing factor SRSF9 in head and neck squamous cell carcinoma and clinical significance
)Objective To analyze the expression， clinical significance， and relationship with tumor immune infiltration of serine/arginine-rich splicing factor 9 （SRSF9） in head and neck squamous cell carcinoma （HNSCC） by bioinformatics methods， and to discuss its mechanism. Methods The expression of SRSF9 in HNSCC and its relationship with clinical pathologic characteristics and prognosis of the patients were analyzed by The Cancer Genome Atlas （TCGA） Database， GSE30784 and GSE13601 datasets in Gene Expression Omnibus （GEO） Database， Clinical Proteomic Tumor Analysis Consortium （CPTAC） Database， Gene Expression Profiling Interactive Analysis （GEPIA） Database， and Kaplan-Meier plotter Database；the variations of SRSF9 gene were examined through cBioPortal Database； ESTIMATE algorithm and The Tumor Immune Estimation Resource （TIMER） Database were used to assess the correlation between SRSF9 expression and tumor microenvironment， as well as tumor immune cell infiltration； LinkedOmics Database was used to analyze the SRSF9 co-expressed genes and their regulatory pathways in the HNSCC；the TCGA SpliceSeq Database was used to analyze the variable splicing events regulated by SRSF9 in the HNSCC；Gene Ontology （GO） functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes （KEGG） signaling pathway enrichment analysis were conducted on the target genes. Results The analysis results from TCGA Database and GSE30784 and GSE13601 datasets in GEO Database showed that the expression level of SRSF9 mRNA in the HNSCC tissue was significantly higher than that in adjacent normal tissue （P<0.01）.The CPTAC Database analysis results showed that compared with normal tissue， the expression level of SRSF9 protein in the HNSCC tissue was significantly increased （P<0.001）.The SRSF9 mRNA expression was associated with pathological grading （P=0.004） and HPV infection （P=0.031） in the patients with HNSCC according to TCGA Database analysis. The GEPIA and Kaplan-Meier plotter Database analysis results showed that high expression of SRSF9 mRNA in the HNSCC tissue was correlated with poorer overall survival （OS） of the patients ［hazard ratio （HR） = 1.40， P=0.019； HR=1.55， P=0.003］. The cBioPortal Database analysis results showed that copy number variation （CNV） of SRSF9 gene occurred in 26.85% in HNSCC， and CNV was positively correlated with SRSF9 mRNA expression levels （r=0.44， P<0.001）. The ESTIMATE algorithm analysis results showed that high expression of SRSF9 mRNA group had lower stromal and immune score， and higher tumor purity than those in low expression of SRSF9 mRNA group（P<0.001）. The TIMER Database analysis results showed there was a positive correlation between the expression of SRSF9 mRNA and CD4+ T lymphocyte infiltration （r=0.186， P<0.001）， and there were negative correlations between the expression level SRSF9 mRNA and B lymphocyte， CD8+ T lymphocyte， and dendritic cell infiltrations （r=－0.269， P<0.001； r=－0.353， P<0.001； r=－0.304， P<0.001）. The co-expressed gene enrichment analysis results showed upregulation of genes related to ribosomes， spliceosomes， and metabolic pathways， and downregulation of genes associated with focal adhesions， cytokines， and cell adhesion molecules. The main pathways involved in SRSF9-related variable splicing target genes were lipid metabolism， glucagon， and tight junctions. Conclusion SRSF9 is highly expressed in HNSCC and is associated with poor prognosis and tumor microenvironment immune cell infiltration， suggesting its potential as a molecular target for the diagnosis， prognosis assessment， and treatment of HNSCC.
Head and neck / Squamous cell carcinoma / Serine/arginine-rich splicing factor 9 / Alternative splicing / Tumor immunity / Bioinformatics
R739.91
| 1 | SUNG H， FERLAY J， SIEGEL R L， et al. Global cancer statistics 2020： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2021，71（3）：209-249. |
| 2 | SCIARRILLO R， WOJTUSZKIEWICZ A， ASSARAF Y G， et al. The role of alternative splicing in cancer： from oncogenesis to drug resistance［J］. Drug Resist Updat， 2020， 53：100728. |
| 3 | FACKENTHAL J D. Alternative mRNA splicing and promising therapies in cancer ［J］. Biomolecules， 2023， 13（3）：561. |
| 4 | FU Y， HUANG B L， SHI Z， et al. SRSF1 and SRSF9 RNA binding proteins promote Wnt signalling-mediated tumorigenesis by enhancing β-catenin biosynthesis［J］. EMBO Mol Med， 2013， 5（5）：737-750. |
| 5 | WANG X Y， LU X S， WANG P， et al. SRSF9 promotes colorectal cancer progression via stabilizing DSN1 mRNA in an m6A-related manner［J］. J Transl Med， 2022， 20（1）：198. |
| 6 | ZHANG G S， LIU B， SHANG H， et al. High expression of serine and arginine-rich splicing factor 9 （SRSF9） is associated with hepatocellular carcinoma progression and a poor prognosis［J］. BMC Med Genomics， 2022， 15（1）：180. |
| 7 | HUI J Y. Regulation of mammalian pre-mRNA splicing［J］. Sci China C Life Sci， 2009，52（3）： 253-260. |
| 8 | CHOI S， CHO N， KIM K K. The implications of alternative pre-mRNA splicing in cell signal transduction［J］. Exp Mol Med， 2023， 55（4）：755-766. |
| 9 | KOZLOVSKI I， SIEGFRIED Z， AMAR-SCHWARTZ A， et al. The role of RNA alternative splicing in regulating cancer metabolism［J］. Hum Genet， 2017， 136（9）：1113-1127. |
| 10 | BRADLEY R K， ANCZUKóW O. RNA splicing dysregulation and the hallmarks of cancer［J］. Nat Rev Cancer， 2023， 23（3）：135-155. |
| 11 | FRANKIW L， BALTIMORE D， LI G D. Alternative mRNA splicing in cancer immunotherapy［J］. Nat Rev Immunol， 2019， 19（11）：675-687. |
| 12 | CHENG R， XU Z C， LUO M， et al. Identification of alternative splicing-derived cancer neoantigens for mRNA vaccine development［J］. Brief Bioinform， 2022， 23（2）： bbab553. |
| 13 | KUMAR K， SINHA S K， MAITY U， et al. Insights into established and emerging roles of SR protein family in plants and animals［J］. Wiley Interdiscip Rev RNA， 2023， 14（3）： e1763. |
| 14 | LUO C L， CHENG Y M， LIU Y G， et al. SRSF2 regulates alternative splicing to drive hepatocellular carcinoma development［J］. Cancer Res， 2017， 77（5）： 1168-1178. |
| 15 | WAN L D， DENG M， ZHANG H H. SR splicing factors promote cancer via multiple regulatory mechanisms［J］. Genes， 2022， 13（9）： 1659. |
| 16 | ZHENG X， PENG Q， WANG L J， et al. Serine/arginine-rich splicing factors： the bridge linking alternative splicing and cancer［J］. Int J Biol Sci， 2020， 16（13）：2442-2453. |
| 17 | JIANG L Y， HUANG J Q， HIGGS B W， et al. Genomic landscape survey identifies SRSF1 as a key oncodriver in small cell lung cancer ［J］. PLoS Genet， 2016， 12（4）： e1005895. |
| 18 | DU J X， LUO Y H， ZHANG S J， et al. Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1［J］. J Exp Clin Cancer Res， 2021， 40（1）：171. |
| 19 | LIU Y D， MAO X， MA Z C， et al. Aberrant regulation of LncRNA TUG1-microRNA-328-3p-SRSF9 mRNA Axis in hepatocellular carcinoma： a promising target for prognosis and therapy［J］. Mol Cancer， 2022， 21（1）：36. |
| 20 | WANG R， SU Q， YIN H Z， et al. Inhibition of SRSF9 enhances the sensitivity of colorectal cancer to erastin-induced ferroptosis by reducing glutathione peroxidase 4 expression［J］. Int J Biochem Cell Biol， 2021， 134：105948. |
| 21 | TACHEZY R， KLOZAR J， RUBENSTEIN L， et al. Demographic and risk factors in patients with head and neck tumors［J］. J Med Virol， 2009， 81（5）： 878-887. |
| 22 | MOLE S， FAIZO A A A， HERNANDEZ-LOPEZ H， et al. Human papillomavirus type 16 infection activates the host serine arginine protein kinase 1 （SRPK1）- splicing factor axis［J］. J Gen Virol， 2020， 101（5）： 523-532. |
| 23 | SOMBERG M， LI X Z， JOHANSSON C， et al. Serine/arginine-rich protein 30c activates human papillomavirus type 16 L1 mRNA expression via a bimodal mechanism［J］. J Gen Virol， 2011， 92（Pt 10）：2411-2421. |
| 24 | TAN E S， KNEPPER T C， WANG X， et al. Copy number alterations as novel biomarkers and therapeutic targets in colorectal cancer［J］. Cancers， 2022， 14（9）： 2223. |
| 25 | ESSERS P B M， VAN DER HEIJDEN M， VOSSEN D， et al. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma［J］. Int J Cancer， 2020， 147（6）：1732-1739. |
| 26 | TURLEY S J， CREMASCO V， ASTARITA J L. Immunological hallmarks of stromal cells in the tumour microenvironment［J］. Nat Rev Immunol，2015，15（11）： 669-682. |
| 27 | CHEN B， LAI J G， DAI D N， et al. JAK1 as a prognostic marker and its correlation with immune infiltrates in breast cancer［J］. Aging （Albany NY）， 2019， 11（23）：11124-11135. |
| 28 | SCHMIDT D R， PATEL R， KIRSCH D G， et al. Metabolomics in cancer research and emerging applications in clinical oncology［J］. CA Cancer J Clin， 2021， 71（4）： 333-358. |
| 29 | BIAN X L， LIU R， MENG Y， et al. Lipid metabolism and cancer［J］. J Exp Med， 2021， 218（1）：1-17. |
| 30 | MIAO X W， WANG B L， CHEN K L， et al. Perspectives of lipid metabolism reprogramming in head and neck squamous cell carcinoma： an overview［J］. Front Oncol， 2022， 12：1008361. |
| 31 | LIN X H， ZHOU W K， LIU Z Q， et al. Targeting cellular metabolism in head and neck cancer precision medicine era： a promising strategy to overcome therapy resistance［J］. Oral Dis， 2023， 29（8）： 3101-3120. |
/
| 〈 |
|
〉 |
AI Summary
